{"id":"W2966010326","doi":"10.1016/j.jaad.2019.04.045","title":"Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study","year":2019,"lang":"en","type":"letter","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Dermatrials Research","funders":"Samsung Bioepis; Cilag; Janssen Biotech; Beijing Novartis Pharma; Sanofi Genzyme; Merck Sharp and Dohme; Samsung; LEO Pharma; Medac; Mitsubishi Tanabe Pharma Corporation; Almirall; Galderma; Allergan; Tartu Ülikool; National Taiwan University; Sanofi; Kyowa Hakko Kirin; Eli Lilly and Company; National Taiwan University Hospital; Purdue Pharma; Fresenius Medical Care North America; Sun Pharma; Novartis Pharmaceuticals Corporation; Dermira; UCB Pharma; Valeant Pharmaceuticals International; Regeneron Pharmaceuticals; Pfizer; Biogen; Novartis; Celgene; Purdue University; Baxalta; Genentech; Biogen Idec; Novartis Pharma; AbbVie; Boehringer Ingelheim; Amgen; GlaxoSmithKline","keywords":"Medicine; Secukinumab; Psoriasis; Dermatology; Plaque psoriasis; Intensive care medicine; Psoriatic arthritis","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002608719,0.000547952,0.001226158,0.0003375957,0.001133825,0.001413202,0.0009251865,0.009349493,0.003146459],"category_scores_gemma":[0.01052864,0.0003066366,0.0005674146,0.0004756425,0.0008369524,0.001295453,0.0002923378,0.008379685,0.002646615],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001270103,"about_ca_system_score_gemma":0.0008922254,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001020547,"about_ca_topic_score_gemma":0.001567892,"domain_scores_codex":[0.9988398,0.0004924744,0.0001666307,0.0001484388,0.0002362645,0.0001165259],"domain_scores_gemma":[0.9948028,0.003372968,0.0003809604,0.0001419347,0.0008811946,0.0004201207],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"observational","study_design_scores_codex":[0.001483245,0.000216668,0.005435841,0.0003185934,0.0001314579,0.01976616,0.0002066215,0.0001266182,0.001128068,0.001319094,0.9155981,0.05426947],"study_design_scores_gemma":[0.002838091,0.001992243,0.02029981,0.0009469421,0.0005922304,0.05691766,0.0006242024,0.003488611,0.003466682,0.0068793,0.9017137,0.0002405693],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.01253673,0.008008788,0.0003406692,0.9311105,0.04168811,0.0000398309,0.0002383879,0.00009649586,0.005940597],"genre_scores_gemma":[0.08533857,0.007454223,0.0006005455,0.730958,0.1631203,0.00006804049,0.0002128801,0.0000745674,0.01217286],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.009349493,"threshold_uncertainty_score":0.01379639,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01229982235036809,"score_gpt":0.24611361904426,"score_spread":0.233813796693892,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}